Page last updated: 2024-12-04

antazoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Antazoline: An antagonist of histamine H1 receptors. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

antazoline : A member of the class of imidazolines that is 2-aminomethyl-2-imidazoline in which the exocyclic amino hydrogens are replaced by benzyl and phenyl groups. Antazoline is only found in individuals that have taken the drug. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2200
CHEMBL ID1305
CHEBI ID84115
SCHEMBL ID9437
MeSH IDM0001292

Synonyms (123)

Synonym
LS-14580
BRD-K99300445-011-02-9
BRD-K99300445-003-03-4
1h-imidazole-2-methanamine, 4,5-dihydro-n-phenyl-n-(phenylmethyl)-
antazoline
DIVK1C_000083
KBIO1_000083
n-(4,5-dihydro-1h-imidazol-2-ylmethyl)-n-(phenylmethyl)aniline
91-75-8
antazolin
2-(n-phenyl-n-benzylaminomethyl)imidazoline
antazolina [inn-spanish]
hsdb 6506
2-phenyl-benzyl-amino-methylimidazolin [german]
brn 0233924
antistine
phenazolin
imidamin
antazoline [inn:ban]
antazolina [spanish]
einecs 202-094-0
2-imidazoline, 2-((n-benzylanilino)methyl)-
azalone
ben-a-hist
vasocon-a
histostab
analergine
antastan
phenazoline
antazolinum [inn-latin]
2-(n-benzylanilinomethyl)-2-imidazoline
4,5-dihydro-n-phenyl-n-phenylmethyl-1h-imidazole-2-methanamine
imidamine
5512-m
antihistal
antistin
antasten
antazolinum [latin]
SPECTRUM_000789
tocris-0791
NCGC00023164-03
SPECTRUM5_000818
BSPBIO_000076
antazoline (inn)
D07458
BPBIO1_000084
PRESTWICK3_000258
PRESTWICK2_000258
BSPBIO_001866
KBIOGR_000582
KBIO2_006405
KBIO3_001366
KBIO2_003837
KBIOSS_001269
KBIO2_001269
SPBIO_002295
PRESTWICK1_000258
SPECTRUM3_000303
SPBIO_001198
NINDS_000083
SPECTRUM2_001259
SPECTRUM4_000141
PRESTWICK0_000258
IDI1_000083
NCGC00016613-02
NCGC00016613-03
CHEMBL1305
chebi:84115 ,
atazoline
DB08799
L000841
n-benzyl-n-(4,5-dihydro-1h-imidazol-2-ylmethyl)aniline
NCGC00016613-04
NCGC00016613-06
NCGC00016613-07
NCGC00016613-05
antazolinum
antazolina
5-25-09-00364 (beilstein handbook reference)
unii-dha8014ss1
dha8014ss1 ,
2-phenyl-benzyl-amino-methylimidazolin
2-((n-benzylanilino)methyl)-2-imidazoline
antazoline [inn]
antazoline [hsdb]
antazoline [mi]
antazoline [mart.]
antazoline [vandf]
antazoline [who-dd]
AKOS015911230
S5946
gtpl7116
CCG-213074
SCHEMBL9437
cid_17275
bdbm76862
n-(4,5-dihydro-1h-imidazol-2-ylmethyl)-n-(phenylmethyl)aniline;hydrochloride
benzyl-(2-imidazolin-2-ylmethyl)-phenyl-amine;phosphoric acid
benzyl-(2-imidazolin-2-ylmethyl)-phenyl-amine;hydrochloride
REYFJDPCWQRWAA-UHFFFAOYSA-N
2-[(n-benzylanilino)methyl]-2-imidazoline
n-benzyl-n-(4,5-dihydro-1h-imidazol-2-ylmethyl)aniline #
allergan a
2-imidazoline, 2-[(n-benzylanilino)methyl]-
n-benzyl-n-((4,5-dihydro-1h-imidazol-2-yl)methyl)aniline
HMS3604F14
AB00053420_20
AB00053420_19
DTXSID3022613
SBI-0051285.P003
benzyl-(4,5-dihydro-1h-imidazol-2-ylmethyl)-phenyl-amine . hcl
NCGC00016613-18
benzyl-(4,5-dihydro-1h-imidazol-2-ylmethyl)-phenyl-amine hcl
FT-0762863
Q771975
BRD-K99300445-011-12-8
antazoline . hcl
A915433
91-75-8 (free base)
CS-0013323
HY-B1067A
n-benzyl-n-[(4,5-dihydro-1h-imidazol-2-yl)methyl]aniline
EN300-6733612

Research Excerpts

Overview

Antazoline appears to be an efficacious agent for termination of AF in real‑world setting. Antazoline is a sufficiently promising antiarrhythmic agent to warrant large-scale controlled studies.

ExcerptReferenceRelevance
"Antazoline appears to be an efficacious agent for termination of AF in real‑world setting. "( Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study).
Balsam, P; Bula, K; Błaszczyk, R; Ceynowa-Sielawko, B; Ćwiek-Rębowska, E; Dembowski, T; Farkowski, M; Kasprzak, JD; Koziński, M; Krzowski, B; Maciąg, A; Miśkowiec, D; Mizia-Stec, K; Ozierański, K; Peller, M; Szołkiewicz, M; Szwed, H; Wańha, W; Wójcik, M; Wróbel, W; Wybraniec, MT, 2022
)
2.47
"Antazoline is a first-generation antihistamine with antiarrhythmic properties. "( Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
Dechering, DG; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Kochhäuser, S; Sterneberg, M, 2018
)
2.23
"Antazoline is a first-generation antihistaminic agent with additional anticholinergic properties and antiarrhythmic potential. "( Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart.
Bińkowski, BJ; Kubiński, P; Lubiński, A; Makowski, M, 2018
)
2.33
"Antazoline is a first-generation antihistaminic drug used primarily in eye drop formulations. "( Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venou
Farkowski, MM; Konka, M; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H, 2019
)
2.34
"Antazoline is an antihistaminic agent with antiarrhythmic properties."( Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation.
Balsam, P; Grabowski, M; Kiliszek, M; Koźluk, E; Kołtowski, Ł; Lodziński, P; Opolski, G; Peller, M; Piątkowska, A, 2015
)
2.58
"Antazoline is a first-generation antihistaminic agent with antiarrhythmic quinidine-like properties. "( Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] hu
Baran, J; Giebułtowicz, J; Kułakowski, P; Piotrowski, R; Wroczyński, P, 2016
)
2.09
"Antazoline is an old antihistaminic and new antiarrhythmic agent with unknown mechanisms of action which recently has been shown to effectively terminate atrial fibrillation. "( Antazoline-insights into drug-induced electrocardiographic and hemodynamic effects: Results of the ELEPHANT II substudy.
Baran, J; Giebułtowicz, J; Gralak-Łachowska, D; Kułakowski, P; Piotrowski, R; Sikorska, A; Soszyńska, M; Wroczyński, P, 2017
)
3.34
"Antazoline is a first generation antihistaminic agent with chinidin-like properties."( Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).
Dabrowski, R; Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H, 2012
)
1.42
"Antazoline is a sufficiently promising antiarrhythmic agent to warrant large-scale controlled studies."( Antazoline therapy of recurrent refractory supraventricular arrhythmias--a preliminary report.
Downar, E; Waxman, MB, 1975
)
2.42

Effects

Antazoline has an effect on electrophysiological parameters of the atrial muscle and has rapid onset of action. It has been reported to achieve high rates of AF conversion to sinus rhythm.

ExcerptReferenceRelevance
"Antazoline has an effect on electrophysiological parameters of the atrial muscle and has rapid onset of action. "( Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart.
Bińkowski, BJ; Kubiński, P; Lubiński, A; Makowski, M, 2018
)
2.33
"Antazoline has been shown to be effective and safe in various patient populations."( Rapid pharmacological cardioversion of recent-onset atrial fibrillation using antazoline in elderly patients.
Farkowski, MM; Gardziejczyk, P; Kowalik, I; Kołakowski, K; Maciąg, A; Pytkowski, M; Szwed, H; Żurawska, M, 2022
)
1.67
"Antazoline has an effect on electrophysiological parameters of the atrial muscle and has rapid onset of action. "( Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart.
Bińkowski, BJ; Kubiński, P; Lubiński, A; Makowski, M, 2018
)
2.33
"Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness and, more importantly, safety in stable CAD patients, have been sparse."( Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.
Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H; Zurawska, M, 2018
)
1.48

Toxicity

Intravenous antazoline was effective and safe in the rapid conversion of non-valvular paroxysmal atrial fibrillation to sinus rhythm in patients without heart failure.

ExcerptReferenceRelevance
" The primary safety endpoint was hospitalization due to the adverse effects of the treatment."( Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department.
Farkowski, MM; Kowalik, I; Maciąg, A; Pytkowski, M; Sterliński, M; Szwed, H; Woźniak, J; Żurawska, M, 2016
)
0.7
"Intravenous antazoline was effective and safe in the rapid conversion of non-valvular paroxysmal atrial fibrillation to sinus rhythm in patients without heart failure."( Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study).
Beckowski, M; Chwyczko, T; Dabrowski, R; Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Syska, P; Szwed, H; Wozniak, J, 2017
)
1.14
" The main endpoints of the study were successful cardioversion of AF and hospitalization due to the adverse effects (AE) of the treatment."( Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.
Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H; Zurawska, M, 2018
)
0.75
"In selected patients with a stable CAD, even with a history of MI, antazoline-based CV of short-duration AF may be an effective and safe therapeutic option."( Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.
Farkowski, MM; Kowalik, I; Maciag, A; Pytkowski, M; Szwed, H; Zurawska, M, 2018
)
0.99

Pharmacokinetics

ExcerptReferenceRelevance
" However, no human pharmacokinetic studies have been conducted with intravenous antazoline."( Application of a novel liquid chromatography/tandem mass spectrometry method for the determination of antazoline in human plasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokinetic and hemodynamic effects of PHenazolinum (ANTazoline mesylate)] hu
Baran, J; Giebułtowicz, J; Kułakowski, P; Piotrowski, R; Wroczyński, P, 2016
)
0.88

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Application of the presented procedure to the analysis of different dosage forms of the compound studied proved successful and compared favourably with official estimations of anatazoline salts."( Polarographic estimation of antazoline hydrochloride.
Atwa, NI; El-Shabouri, SR; Issa, IM; Omar, NM, 1978
)
0.55
" The procedure was applied to the analysis of different antazoline dosage forms."( Improved spectrophotometric determination of antazoline.
Omar, NM, 1978
)
0.76
" The three preparations were found to vary greatly in patient comfort and acceptability but were not different in their ability to ameliorate the itching, tearing, redness, edema and discomfort when dosed topically for the relief of allergic conjunctivitis."( A double-masked comparison of ocular decongestants as therapy for allergic conjunctivitis.
deFaller, JM; Lanier, BQ; Smith, JP; Tremblay, N, 1983
)
0.27
" All methods were applied successfully for the determination of the selected drugs in their combined dosage form proving that the classical spectrophotometric methods can still be used successfully in analysis of binary mixture using minimal data manipulation rather than recent methods which require relatively more steps."( Comparative study between recent methods manipulating ratio spectra and classical methods based on two-wavelength selection for the determination of binary mixture of antazoline hydrochloride and tetryzoline hydrochloride.
Abd-El Rahman, MK; Abdel-Halim, LM; El Sanabary, HF; Ramadan, NK; Salem, MY, 2016
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
cholinergic antagonistAny drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
imidazolinesDiazoline compounds having the nitrogen atoms at the 1- and 3-positions and a double bond at an unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Antazoline H1-Antihistamine Action87

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency23.71500.000811.382244.6684AID686978
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926; AID938
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency11.23230.00207.533739.8107AID891
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency39.81070.010323.856763.0957AID2662
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.00250.891312.067628.1838AID1487
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency0.50121.000010.475628.1838AID901
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H1 receptorCavia porcellus (domestic guinea pig)Kd0.07240.00080.12280.9550AID1359268; AID1495367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1359268Antagonist activity at H1 receptor in guinea pig ileum assessed as inhibition of histamine-induced ileum contraction measured after 15 mins2018European journal of medicinal chemistry, May-25, Volume: 152Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H
AID1633045Antagonist activity at histamine H1 receptor in guinea-pig ileum assessed as inhibition of histamine-induced contractions incubated for 15 mins
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1638968Antagonist activity at histamine H1 receptor in guinea-pig ileum assessed as inhibition of histamine-induced contractions after 15 mins2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Alkyl derivatives of 1,3,5-triazine as histamine H
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID87696Relative antagonistic activity against Histamine H2 receptor1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Bioisosteric design of conformationally restricted pyridyltriazole histamine H2-receptor antagonists.
AID179056Compound was evaluated in vivo for inhibition of Ovalbumin induced rhinitis in anesthetized rats after topical administration (nasal perfusion).1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1495367Antagonist potency at histamine H1 receptor in guinea-pig ileum assessed as inhibition of histamine-induced contractions after 15 mins
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (192)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990125 (65.10)18.7374
1990's20 (10.42)18.2507
2000's9 (4.69)29.6817
2010's28 (14.58)24.3611
2020's10 (5.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.35 (24.57)
Research Supply Index5.47 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index89.62 (26.88)
Search Engine Supply Index2.49 (0.95)

This Compound (46.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (9.26%)5.53%
Reviews2 (0.93%)6.00%
Case Studies6 (2.78%)4.05%
Observational1 (0.46%)0.25%
Other187 (86.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Efficacy and Safety of Antazoline in Comparison to Propafenone in Conversion of Paroxysmal Atrial Fibrillation to Sinus Rhythm - a Single Center, Randomized, Double-blinded Study (the AnProAF Study). [NCT05720572]Phase 4105 participants (Anticipated)Interventional2019-09-01Recruiting
Clinical Efficacy of Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation - a Single Centre, Randomized, Double-blind, Placebo-controlled Study (the AnPAF Study) [NCT01527279]Phase 474 participants (Actual)Interventional2012-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]